

***Listing of the Claims***

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently amended) A method of reducing the viability of a tumor cell, comprising administering to the tumor cell a virus, such that the virus is delivered to the tumor cell,

wherein said virus is a vesicular stomatitis virus and said tumor cell is a hematopoietic tumor cell and

wherein the virus is contained in a cell infected with the virus and the administering comprises administering the virus-infected cell.

2. (Withdrawn) The method of claim 1, wherein the tumor cell is selected from the group consisting of ovarian carcinoma, leukaemia, lung carcinoma, and colon carcinoma.

3. (Withdrawn) The method of claim 1, wherein the tumor cell is a carcinoma.

4. (Withdrawn) The method of claim 3, wherein the carcinoma is a lung carcinoma.

5. (Cancelled)

6. (Previously presented) The method of claim 1, wherein the hematopoietic tumor cell is a leukemia, a lymphoma, or a myeloma.

7. (Previously presented) The method of claim 1, wherein the hematopoietic tumor cell is a leukemia.

8. (Original) The method of claim 7, wherein the leukemia is acute myelogenous leukemia.

9. (Original) The method of claim 7, wherein the leukemia is chronic myelogenous leukemia.

10. (Original) The method of claim 7, wherein the leukemia is promyelocytic leukemia.

11. (Original) The method of claim 7, wherein the leukemia is T cell leukemia.

12. (Previously presented) The method of claim 1, wherein the hematopoietic tumor cell is a lymphoma.

13. (Previously presented) The method of claim 1, wherein the hematopoietic tumor cell is a myeloma.

14. (Withdrawn) The method of claim 1, wherein the tumor cell is a sarcoma.

15. (Withdrawn) The method of claim 14, wherein the sarcoma is an osteosarcoma.

16. (Withdrawn) The method of claim 14, wherein the sarcoma is a fibrosarcoma.

17. (Withdrawn) The method of claim 1, wherein the tumor cell is a neuroendocrine tumor.

18. (Cancelled)

19. (Original) The method of claim 1, wherein the tumor cell is PKR-/-; STAT1-/-; or both PKR-/- and STAT1-/-.

20-23. (Cancelled)

24. (Currently amended) The method of claim 1, further comprising administering interferon to the tumor cell prior to administering VSV, such that the interferon is delivered to the tumor cell.

25. (Previously presented) The method of claim 1, wherein the virus is unable to inactivate PKR activity within the tumor cell.

26. (Previously presented) The method of claim 1, wherein the virus is an attenuated strain of vesicular stomatitis virus.

27. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M1.

28. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M2.

29. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M3.

30. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M4.

31. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M5.

32. (Currently amended) The method of claim 1, wherein the tumor cell is in a mammalian subject ~~and the virus is administered to the tumor cell by intravenous, intranasal, intraperitoneal or intratumoral administration to the subject.~~

33. (Currently amended) The method of claim 32, wherein the mammalian subject is a human ~~or a non human mammal~~.

34. (Currently amended) The method of claim 32, wherein the ~~virus is contained in a cell line infected with the virus and the administration administering~~ comprises administering the virus-infected cell ~~line~~ to the subject by a route selected from intratumorally, intravenously and intraperitoneally.

35. (Currently amended) A method of reducing the viability of a tumor cell within a population of cells comprising administering a vesicular stomatitis virus to the population of cells, such that the virus is delivered to the population of cells,

wherein the virus is contained in a cell infected with the virus and the administering  
comprises administering the virus-infected cell,

wherein the population of cells comprises hematopoietic tumor cells and non-tumor cells and

wherein the virus is able to selectively reduce the viability of the hematopoietic tumor cells.

36. (Original) The method of claim 35, wherein the virus is unable to inactivate PKR activity in the tumor cell.

37. (Original) The method of claim 36, further comprising treating the population of cells with interferon prior to administering the virus.

38-63. (Cancelled)

64. (New) The method of claim 35, wherein the hematopoietic tumor cells are leukemia cells.

65. (New) The method of claim 64, wherein the leukemia cells are acute myelogenous leukemia cells.

66. (New) The method of claim 64, wherein the leukemia cells are chronic myelogenous leukemia cells.

67. (New) The method of claim 64, wherein the leukemia cells are promyelocytic leukemia cells.

68. (New) The method of claim 64, wherein the leukemia cells are T cell leukemia cells.

69. (New) The method of claim 35, wherein the hematopoietic tumor cells are lymphoma cells.

70. (New) The method of claim 35, wherein the hematopoietic tumor cells are myeloma cells.

71. (New) The method of claim 35, wherein the tumor cells are PKR-/-; STAT1-/-; or both PKR-/- and STAT1-/-.

72. (New) The method of claim 35, wherein the virus is an attenuated strain of vesicular stomatitis virus.

73. (New) The method of claim 35, wherein the virus is vesicular stomatitis virus strain M1.

74. (New) The method of claim 35, wherein the virus is vesicular stomatitis virus strain M2.

75. (New) The method of claim 35, wherein the virus is vesicular stomatitis virus strain M3.

76. (New) The method of claim 35, wherein the virus is vesicular stomatitis virus strain M4.

77. (New) The method of claim 35, wherein the virus is vesicular stomatitis virus strain M5.

78. (New) The method of claim 35, wherein the administering of the vesicular stomatitis virus to the population of cells is performed *in vitro*.

79. (New) The method of claim 32, wherein the mammalian subject is a non-human mammal.

80. (New) The method of claim 32, further comprising treating the mammalian subject with an interferon.